#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to understand cannabis potency’s impact on driving impairment to counsel patients about safety risks, as higher-THC products are increasingly available and may impair driving performance more severely than lower-potency alternatives. This evidence helps inform patient discussions about responsible use timing and dosing, particularly for patients operating vehicles or machinery. Healthcare providers can use these findings to screen for driving-related risks during cannabis use assessments and adjust counseling based on product potency rather than cannabis use alone.
This study examined how cannabis potency affects driving performance in a simulated driving environment, addressing a critical gap in understanding dose-dependent impairment risks. The research demonstrates that higher potency cannabis products produce greater deficits in driving-related skills including lane maintenance, reaction time, and overall vehicle control compared to lower potency products. These findings have direct clinical relevance for physicians counseling patients about cannabis use and driving safety, particularly as the cannabis market increasingly features high-potency products that may carry underappreciated impairment risks. The data support the need for standardized patient education about potency levels and driving restrictions, similar to alcohol impairment guidance. Clinicians should counsel patients that cannabis potency significantly influences impairment severity and duration, and recommend abstinence from driving for several hours after use of high-potency products, with individualized guidance based on product THC concentration.
“What this research confirms is that we need to counsel patients on impairment timing and individual variability rather than apply blanket restrictions, because the relationship between THC potency and driving impairment isn’t linear across all users, and some patients tolerate higher potencies without measurable cognitive deficits while others show significant impairment at lower doses.”
🚗 Recent evidence on cannabis potency and driving impairment underscores a significant gap between patient perceptions and actual cognitive effects, particularly as THC concentrations in available products have increased substantially over the past decade. Higher-potency cannabis produces measurable decrements in simulated driving performance, yet many patients report using cannabis before driving and may not recognize impairment, especially if they have developed tolerance to subjective effects. Clinicians should recognize that tolerance to psychoactive symptoms does not confer protection against impairment of reaction time, attention, and motor coordination required for safe driving. When counseling patients about cannabis use, providers should explicitly discuss driving safety and clarify that the absence of feeling “high” does not indicate safe driving ability, and should screen for driving patterns in patients who use higher-potency products. This conversation becomes increasingly important as product potency continues to rise and as more patients integrate cannabis into their daily medication regimens.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: